Moving forward with Takeda's live chimeric tetravalent dengue vaccine

Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100...

Full description

Saved in:
Bibliographic Details
Main Author: Wilder-Smith, Annelies
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2017
Subjects:
Online Access:https://hdl.handle.net/10356/83617
http://hdl.handle.net/10220/42732
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-83617
record_format dspace
spelling sg-ntu-dr.10356-836172020-11-01T05:21:04Z Moving forward with Takeda's live chimeric tetravalent dengue vaccine Wilder-Smith, Annelies Lee Kong Chian School of Medicine (LKCMedicine) Dengue Vaccine Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100 million individuals per year,1 the approval of the first dengue vaccine developed by Sanofi Pasteur (CYD-TDV) was a welcome step forward.2 However, the first vaccine does not present a simple solution. Accepted version 2017-06-20T04:31:58Z 2019-12-06T15:26:50Z 2017-06-20T04:31:58Z 2019-12-06T15:26:50Z 2017 Journal Article Wilder-Smith, A. (2017). Moving forward with Takeda's live chimeric tetravalent dengue vaccine. The Lancet Infectious Diseases, 17(6), 566-568. 1473-3099 https://hdl.handle.net/10356/83617 http://hdl.handle.net/10220/42732 10.1016/S1473-3099(17)30165-2 en The Lancet Infectious Diseases © 2017 Elsevier Ltd. This is the author created version of a work that has been peer reviewed and accepted for publication by The Lancet Infectious Diseases, Elsevier Ltd. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1016/S1473-3099(17)30165-2]. 4 p. application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Dengue
Vaccine
spellingShingle Dengue
Vaccine
Wilder-Smith, Annelies
Moving forward with Takeda's live chimeric tetravalent dengue vaccine
description Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100 million individuals per year,1 the approval of the first dengue vaccine developed by Sanofi Pasteur (CYD-TDV) was a welcome step forward.2 However, the first vaccine does not present a simple solution.
author2 Lee Kong Chian School of Medicine (LKCMedicine)
author_facet Lee Kong Chian School of Medicine (LKCMedicine)
Wilder-Smith, Annelies
format Article
author Wilder-Smith, Annelies
author_sort Wilder-Smith, Annelies
title Moving forward with Takeda's live chimeric tetravalent dengue vaccine
title_short Moving forward with Takeda's live chimeric tetravalent dengue vaccine
title_full Moving forward with Takeda's live chimeric tetravalent dengue vaccine
title_fullStr Moving forward with Takeda's live chimeric tetravalent dengue vaccine
title_full_unstemmed Moving forward with Takeda's live chimeric tetravalent dengue vaccine
title_sort moving forward with takeda's live chimeric tetravalent dengue vaccine
publishDate 2017
url https://hdl.handle.net/10356/83617
http://hdl.handle.net/10220/42732
_version_ 1683493779057672192